MPs lobby Merck for U.K. Vioxx deal

Now Parliament wants Merck to give U.K. patients a cut. MPs are hopping mad that the company is settling with U.S. Vioxx claimants to the tune of $4.85 billion but refuses to make a deal in Britain. They're inviting the drugmaker to the table this week as the deadline for court action against Merck approaches.

Some 500 British patients have been unable to sue in part because they can't afford to risk paying Merck's legal bills if they lose. Contingency fee lawyers consider filing suit against the drug giant too risky, The Times reports. So 44 MPs have signed a motion calling the situation "unjust," and the government has been asked to investigate.

- see the article in The Times
- check out the other Pharmalot item

Related Articles:
Vioxx plaintiffs sign on, deal proceeds. Report
Merck settling Vioxx claims for $4.85B. Report
Vioxx deal faces pitfalls. Report
Court appoints Vioxx special master. Report
Vioxx settlement spawns mega-chatter. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.